Physician profile
Brian A Rowan
NPI 1821059510
$1,382.71
in general payments reported to CMS, 2019-2025
10 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $660 · 2021: $22.75 · 2022: $46.69 · 2023: $14.44 · 2024: $37.92 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $219.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $996.85 | 2019-2025 | Blueprint Patient Specific Instrumentation |
| Arthrex, INC. | $153.37 | 2019 | |
| Rsw Medical Company, INC. | $50.79 | 2019 | |
| Ferring Pharmaceuticals INC. | $47.71 | 2024-2025 | Euflexxa |
| Depuy Synthes Sales INC. | $33.70 | 2025 | Na |
| Mml US, INC. | $24.22 | 2025 | Reactiv8 |
| Heron Therapeutics, INC. | $23.70 | 2024 | Zynrelef |
| Nalu Medical, INC. | $20.87 | 2025 | Nalu Neurostimulation System |
| Merck Sharp & Dohme LLC | $16.97 | 2025 | Bridion |
| Vertex Pharmaceuticals Incorporated | $14.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Rowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.